Eli Lilly CEO Dave Ricks told CNBC that Medicare will begin covering obesity drugs later this year under agreements struck with the administration. Lilly expects coverage to take effect immediately after its experimental oral GLP-1 candidate, orforglipron, receives approval. Ricks noted that broad insurance reimbursement would dramatically expand patient access beyond the cash-pay environment that competitors’ early adopters have relied on. Management plans a full commercial launch in the second quarter, timed to coincide with the new coverage rules, which could materially boost initial uptake and revenue visibility for the pill.

On Friday, Lilly announced it will invest $3.5 billion to build a biomanufacturing facility in Lehigh Valley, Pennsylvania, aimed at producing its next-generation obesity injections, including retatrutide. Construction is slated to begin later this year, with operations targeted for 2031. The site will create 850 permanent positions and 2,000 construction jobs. This plant marks Lilly’s fourth major U.S. investment in domestic capacity since 2020 and underscores the company’s commitment to scaling production for high-demand GLP-1 and multi-agonist drugs, ensuring supply security as global demand accelerates.

Data from MediaRadar and IQVIA reveal that Lilly increased its U.S. advertising investment in 2025 to approximately $214 million, up from $2 million the prior year, focusing on Zepbound and its diabetes treatment Mounjaro. Despite outspending by Novo Nordisk—whose combined spend on Wegovy and Ozempic reached about $487 million—Lilly captured roughly 60% of the U.S. obesity drug market. Clinical trial results published in late 2024 showed Zepbound users lost 47% more weight than Wegovy users, bolstering Lilly’s market position and providing a durable competitive advantage as promotional budgets normalize.

On Mad Money, host Jim Cramer identified three drivers for Lilly’s stock momentum: the imminent Medicare coverage announcement, the upcoming orforglipron launch, and robust pipeline data for retatrutide. He emphasized that investors should watch next week’s regulatory calendars and the company’s second-quarter guidance call for updated trial readouts. Cramer also pointed to management’s disciplined capital allocation—evident in the multi-billion-dollar plant build—and strong free cash flow generation as supportive of Lilly’s valuation premium within the pharmaceutical sector.